Wyeth can't keep Effexor settlements secret; AZ's nasal flu vax gets European rec;

 @FiercePharma: Woodcock: FDA may tighten generic-drug rules. Article | Follow @FiercePharma

> Handing Wyeth a setback in a patent infringement suit over its antidepressant Effexor XR, a federal judge says the pharmaceutical manufacturer can't claim its out-of-court settlements in earlier cases are confidential. Report

> AstraZeneca's nasal flu vaccine, already on sale in the U.S. as FluMist, has been recommended for pediatric approval in Europe, although it is unlikely to go on sale until 2012. Story

> Novo Nordisk launched its first consumer ad push for Victoza, its diabetes drug, with print ads and a refurbished website. Item

> K-V Pharmaceutical said it is opening a new generic drug business to replace its Ethex unit, which is being closed after a series of product recalls that resulted in criminal charges. K-V release | News

> Hospira is finally launching a generic version of Pfizer's injectable antibiotic Zosyn in the U.S. after years of trying. Article

Biotech News

 @FierceBiotech: The Top 10 Phase III Failures of 2010. Article | Follow @FierceBiotech

 @JohnCFierce: Lilly gets hit again. Teplizumab fails Ph3 for diabetes. MacroGenics gets hurt on this one as well. Article | Follow @JohnCFierce

> Aastrom puts hopes in promising CLI therapy. News

> Lilly's setbacks could lead to Amylin buyout, other deals. Article

> Dicerna gets another $4M for RNAi work. Report 

> Diamyd to divide operations. Story

> Group plots new biotech building in MD. Report

And Finally... GlaxoSmithKline is ramping up its solar-energy capacity at its Research Triangle, N.C., operations, adding another 220-kilowatt system next month. Report